NOVO B Stock Overview
Engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 4/6 |
| Financial Health | 4/6 |
| Dividends | 3/6 |
Novo Nordisk A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 750.90 |
| 52 Week High | DKK 1,033.20 |
| 52 Week Low | DKK 645.00 |
| Beta | 0.16 |
| 11 Month Change | -5.76% |
| 3 Month Change | -17.66% |
| 1 Year Change | 4.77% |
| 33 Year Change | 110.78% |
| 5 Year Change | 293.97% |
| Change since IPO | 27,762.72% |
Recent News & Updates
Solid Earnings May Not Tell The Whole Story For Novo Nordisk (CPH:NOVO B)
Nov 13
Novo Nordisk A/S (CPH:NOVO B) Just Released Its Third-Quarter Earnings: Here's What Analysts Think
Nov 09Recent updates
Solid Earnings May Not Tell The Whole Story For Novo Nordisk (CPH:NOVO B)
Nov 13Novo Nordisk A/S (CPH:NOVO B) Just Released Its Third-Quarter Earnings: Here's What Analysts Think
Nov 09Is Novo Nordisk A/S (CPH:NOVO B) Trading At A 31% Discount?
Nov 01Novo Nordisk A/S' (CPH:NOVO B) P/E Still Appears To Be Reasonable
Oct 09Is Novo Nordisk (CPH:NOVO B) Using Too Much Debt?
Jul 27Should You Be Adding Novo Nordisk (CPH:NOVO B) To Your Watchlist Today?
Jul 05A Look At The Fair Value Of Novo Nordisk A/S (CPH:NOVO B)
Jun 09Novo Nordisk's (CPH:NOVO B) Promising Earnings May Rest On Soft Foundations
May 09Results: Novo Nordisk A/S Beat Earnings Expectations And Analysts Now Have New Forecasts
May 04The Price Is Right For Novo Nordisk A/S (CPH:NOVO B)
Apr 28Does Novo Nordisk (CPH:NOVO B) Have A Healthy Balance Sheet?
Apr 14Do Novo Nordisk's (CPH:NOVO B) Earnings Warrant Your Attention?
Mar 18Novo Nordisk A/S' (CPH:NOVO B) Price In Tune With Earnings
Dec 30Novo Nordisk (CPH:NOVO B) Seems To Use Debt Rather Sparingly
Dec 12Estimating The Intrinsic Value Of Novo Nordisk A/S (CPH:NOVO B)
Nov 24Shareholder Returns
| NOVO B | DK Pharmaceuticals | DK Market | |
|---|---|---|---|
| 7D | 5.6% | 3.0% | 3.4% |
| 1Y | 4.8% | 5.7% | 7.5% |
Return vs Industry: NOVO B matched the Danish Pharmaceuticals industry which returned 5.7% over the past year.
Return vs Market: NOVO B underperformed the Danish Market which returned 7.5% over the past year.
Price Volatility
| NOVO B volatility | |
|---|---|
| NOVO B Average Weekly Movement | 4.3% |
| Pharmaceuticals Industry Average Movement | 5.3% |
| Market Average Movement | 4.3% |
| 10% most volatile stocks in DK Market | 10.5% |
| 10% least volatile stocks in DK Market | 2.5% |
Stable Share Price: NOVO B has not had significant price volatility in the past 3 months compared to the Danish market.
Volatility Over Time: NOVO B's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1923 | 71,880 | Lars Jorgensen | www.novonordisk.com |
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas.
Novo Nordisk A/S Fundamentals Summary
| NOVO B fundamental statistics | |
|---|---|
| Market cap | DKK 3.34t |
| Earnings (TTM) | DKK 94.72b |
| Revenue (TTM) | DKK 270.58b |
35.2x
P/E Ratio12.3x
P/S RatioIs NOVO B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NOVO B income statement (TTM) | |
|---|---|
| Revenue | DKK 270.58b |
| Cost of Revenue | DKK 41.51b |
| Gross Profit | DKK 229.07b |
| Other Expenses | DKK 134.35b |
| Earnings | DKK 94.72b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 05, 2025
| Earnings per share (EPS) | 21.32 |
| Gross Margin | 84.66% |
| Net Profit Margin | 35.01% |
| Debt/Equity Ratio | 47.3% |
How did NOVO B perform over the long term?
See historical performance and comparison